Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,958 total articles

Independent Fire Testing Confirms Eos Z3 Battery System Exhibited No Thermal Runaway, No Sustained Fire, and No Propagation Under Abuse Testing; Company Receives ISO 14001 Certification

Independent Fire Testing Confirms Eos Z3 Battery System Exhibited No Thermal Runaway, No Sustained Fire, and No Propagation Under Abuse Testing; Company Receives ISO 14001 Certification

Eos Energy Enterprises announced that its Z3 battery modules passed independent destructive fire testing with no thermal runaway, sustained fire, or propagation, meeting new NFPA 855 safety standards for large-scale energy storage. The company also received ISO 14001 certification, underscoring its commitment to environmental management. These resu…

FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing

FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing

FibroBiologics announced that the USPTO issued a Notice of Allowance for their patent application covering methods of treating wounds using topical 3D spheroid fibroblasts and fibroblast-derived materials. This patent supports their lead clinical program, CYWC628, being evaluated for diabetic foot ulcers, a challenging chronic wound.

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

Entera Bio announced positive feedback from the FDA on its Phase 3 study protocol for EB613, the first oral anabolic tablet for treating osteoporosis in postmenopausal women. The Phase 3 trial, planned to start in late 2026 with topline data expected in late 2028, will evaluate EB613's efficacy in improving total hip bone mineral density. The NDA s…

NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization

NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization

NewGenIVF Group Limited has issued 3,666,667 new shares to acquire a 10% stake in AI-focused K25.ai, raising its total shares to over 10 million and increasing market capitalization to $7.6 million. This capital boost supports NewGen's strategic pivot towards AI, digital platforms, and prediction markets in APAC, backed by a $10 million investment …

Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

Vivos Therapeutics, Inc., a NASDAQ-listed medical device company specializing in sleep apnea treatments, has extended its financing agreement timeframe with Streeterville Capital to August 31, 2026. This extension allows the company more time to raise equity in an organized manner and for Streeterville to convert up to $4.5 million of outstanding d…

Kingstone Appoints Sylvie Widjaja to Lead California Business

Kingstone Appoints Sylvie Widjaja to Lead California Business

Kingstone Companies, Inc. announced the appointment of Sylvie Widjaja as Vice President, California Business Leader, to spearhead the company's entry into the California homeowners insurance market on an excess and surplus lines basis. Widjaja brings over 20 years of California market experience, including leadership roles at Mercury Insurance Grou…

Saratoga Investment Corp. to Report Fiscal First Quarter 2027 Financial Results and Hold Conference Call

Saratoga Investment Corp. to Report Fiscal First Quarter 2027 Financial Results and Hold Conference Call

Saratoga Investment Corp., a business development company specializing in customized financing for U.S. middle-market businesses, will release its fiscal first quarter 2027 financial results on July 7, 2026, with a follow-up conference call scheduled for July 8, 2026. The company focuses on senior and unitranche leveraged loans, mezzanine debt, and…

Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery

Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery

Nexentis Technologies' wholly owned subsidiary, MitoCareX Bio, has entered a strategic partnership with AI research lab Boltz to combine their proprietary MITOLINE® structural modeling with Boltz's biomolecular AI models. This collaboration aims to accelerate the discovery of novel small-molecule therapies targeting solute carrier (SLC) proteins re…

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial

Clearmind Medicine has announced the completion of treatment for all participants in the initial phase (Part A) of its ongoing FDA-regulated Phase I/II clinical trial evaluating CMND-100, a novel therapeutic for Alcohol Use Disorder. The company is analyzing data and plans to proceed to the next stage of clinical development, advancing its non-hall…

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Verrica Pharmaceuticals announced dosing of the first U.S. patient in the COVE-3 Phase 3 clinical trial evaluating YCANTH® (VP-102) for common warts. With a global Phase 3 program ongoing, including its Japanese partner Torii Pharmaceutical, the company targets a significant market with no current FDA-approved treatments. Positive Phase 2 results a…

Westport Announces US$10 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Westport Announces US$10 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Westport Fuel Systems Inc. announced a definitive agreement for a $10 million registered direct offering of common shares and a concurrent private placement of warrants priced at-the-market under Nasdaq rules. The company expects to use the net proceeds for working capital and general corporate purposes. If private placement warrants are exercised,…

LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

LifeMD, a Nasdaq-listed virtual care provider, announced an exclusive telehealth co-marketing partnership with Antares Pharma to launch a direct-to-patient self-pay program for XYOSTED®, the FDA-approved once-weekly testosterone enanthate auto-injector. Launching in July 2026 across 37 states, the program offers virtual evaluation, diagnosis, and h…

Kandi Technologies Accelerates Global Expansion

Kandi Technologies Accelerates Global Expansion

Kandi Technologies Group, Inc. reports accelerated international expansion of its off-road vehicle business. The company's products are now available in 35 countries and regions, with focused growth in Africa, Southeast Asia, Latin America, and the Middle East through a dual strategy of order expansion and brand localization. Key new dealer partner…

Veea Strengthens Executive Leadership Team to Accelerate its Commercial Growth and Market Expansion

Veea Strengthens Executive Leadership Team to Accelerate its Commercial Growth and Market Expansion

Veea Inc., a NASDAQ-listed leader in AI-powered edge infrastructure, has promoted Greg Deisher to COO, Mark Tubinis to Executive VP, and appointed Thomas Latiolais as CMO. These leadership changes aim to accelerate revenue growth, strengthen operational execution, and drive global market expansion across enterprise, industrial, and AI-enabled secto…

Tyson® Debuts New Garlic & Herb, BBQ, and Harissa Chicken Cups

Tyson® Debuts New Garlic & Herb, BBQ, and Harissa Chicken Cups

Tyson Foods has launched three new flavors—Garlic & Herb, BBQ, and Harissa—for its Tyson Chicken Cups, following strong consumer reception and recognition as Product of the Year in the Protein Snack category. The new offerings cater to diverse consumer taste preferences, especially among Millennials and Gen Z, and reinforce Tyson's position in conv…

Refinity Secures Exclusive License to PNNL Catalyst Technology to Convert Olefins into Circular Hydrocarbon Liquids for SAF Production

Refinity Secures Exclusive License to PNNL Catalyst Technology to Convert Olefins into Circular Hydrocarbon Liquids for SAF Production

Refinity, a subsidiary of Innventure, Inc. (NASDAQ: INV), has secured an exclusive license from Pacific Northwest National Laboratory (PNNL) to commercialize catalyst technology that converts waste plastic-derived light olefins into distillate-range hydrocarbons suitable for sustainable aviation fuel (SAF), renewable diesel, and lubricants. The com…

BitFuFu Announces US$5 Million Share Repurchase Program

BitFuFu Announces US$5 Million Share Repurchase Program

BitFuFu Inc., a leading Bitcoin mining company listed on NASDAQ under ticker FUFU, has approved a $5 million share repurchase program to be executed over the next 24 months. The program reflects the company's confidence in its long-term growth prospects and aims to enhance shareholder value while maintaining financial flexibility to invest in expan…

Country Stampede Breaks Attendance Records

Country Stampede Breaks Attendance Records

Kustom Entertainment, Inc. announced record attendance exceeding 32,000 for its 30th anniversary Country Stampede Festival in Kansas. The company reported multiple ticket classes sold out, signaling strong consumer demand. Additionally, Kustom has partnered with Ruffin Properties to host multi-season music festivals at Gilley's Gambling Hall Park C…

Rezolve Ai Powers New Mashreq and Visa Everyday Cashback Program, Bringing AI-Enabled Card Linked Offers to UAE Cardholders

Rezolve Ai Powers New Mashreq and Visa Everyday Cashback Program, Bringing AI-Enabled Card Linked Offers to UAE Cardholders

Rezolve Ai announces its Reward platform is powering Everyday Cashback, a new Visa Card Linked Offers program launched by Mashreq bank in the UAE. This initiative allows Mashreq cardholders to receive up to 20% automated cashback at hundreds of merchants, utilizing AI-driven personalized offers. The launch expands Rezolve Ai's presence into payment…

NorthStar Secures Over CAD$40M with 3 Canadian Space Division to Advance Sovereign Space Domain Awareness

NorthStar Secures Over CAD$40M with 3 Canadian Space Division to Advance Sovereign Space Domain Awareness

NorthStar Earth & Space, a Canadian-based company specializing in Space Situational and Domain Awareness, has secured commercial services contracts worth over CAD$40 million with the Royal Canadian Air Force's 3 Canadian Space Division. This partnership aims to integrate NorthStar's space-based surveillance technology to improve Canada's mission re…

Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer’s Disease Biomarkers

Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer’s Disease Biomarkers

Aptorum Group Limited (NASDAQ: APM) announced a collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics to develop blood-based biomarker tests for Alzheimer’s disease. The focus is on protein and microRNA biomarkers such as p-Tau 217, amyloid 42/40, and neurofilament light to improve non-invasive diagnosis and monitoring of neuro…